A Phase 3, Randomized, Double-Blind, Placebo-Controlled,

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib
StatusFinished
Effective start/end date5/5/0812/31/12

Funding

  • INFINITY PHARMACEUTICALS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.